Paris, February 8^th 2018 - 2017 will go down in history as the year Ceva Santé Animale (Ceva) achieved growth of 20% and broke the Billion Euro barrier for the first time with sales of €1.1 billion. This performance consolidates its position as the 6th largest animal health company and leading French multinational in the sector.

A year of growth based on successful integrations

In 2017, Ceva grew its business by 20%, achieving turnover of €1.1 billion. Performance was strong across all geographical regions. The global sales are split as follows Europe - 34%, Africa-Middle East-Eastern Europe-Turkey - 19%, North America-Pacific – 16%, Latin America – 15% and Asia – 13%.

In terms of product portfolios, the Swine business recorded the biggest increase (up 66%, representing 16% of sales) due mainly to the acquisition of 4 ex-Merial vaccines. Ruminant sales were up 40%, (20% of turnover) driven by the acquisition of Brazilian firms Hertape and Inova. Companion Animal sales grew 12%, (29% of turnover), with Poultry up 8%, (35% of turnover).

Ceva Chairman and CEO, Dr. Marc Prikazsky delighted with these latest results said: “Our strong growth can be explained largely through our most recent acquisitions, Hertape and Inova in Brazil, but equally the purchase of a number of ex-Merial products and the acquisitions of Ebvac, China, Polchem in India and Biovac, France. However, our organic growth was also a driver, achieving an historic 9% increase (at constant scope and exchange rates). This success is due to the hard work of all our teams, in particular those in Libourne, for the smooth integration of these new companies, as well as the R&D, industrial and logistics teams for the development of such innovative new products as Feliscratch by Feliway®, Zeleris® and Smartvac®.”